74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
VolitionRX Ltd
Closed
0.54 -5.26
Overview
Share price change
24h
Min
0.54
Max
0.56
Income | 1.2M -5.8M |
|---|---|
Sales | 79K 475K |
EPS | -0.07 |
Profit margin | -1,226.82 |
Employees | 96 |
EBITDA | 1.2M -5.4M |
Next Earnings | 24 Mar 2025 |
|---|
Market Cap | 56M |
|---|---|
Previous open | 5.8 |
Previous close | 0.54 |
VolitionRX Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
VolitionRX Ltd Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About VolitionRX Ltd
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
